1. Home
  2. CABR vs INTS Comparison

CABR vs INTS Comparison

Compare CABR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caring Brands Inc.

CABR

Caring Brands Inc.

HOLD

Current Price

$0.66

Market Cap

12.8M

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

SELL

Current Price

$2.46

Market Cap

13.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CABR
INTS
Founded
2020
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
13.7M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CABR
INTS
Price
$0.66
$2.46
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $18.67
AVG Volume (30 Days)
★ 131.4K
13.8K
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $4,215.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$0.22
52 Week High
$1.84
$8.06

Technical Indicators

Market Signals
Indicator
CABR
INTS
Relative Strength Index (RSI) 37.14 28.84
Support Level N/A $0.22
Resistance Level $1.41 $4.17
Average True Range (ATR) 0.20 0.27
MACD -0.02 -0.06
Stochastic Oscillator 13.64 13.88

Price Performance

Historical Comparison
CABR
INTS

About CABR Caring Brands Inc.

Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: